Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) Target Price at $32.00

OnKure Therapeutics, Inc. (NASDAQ:OKUR) has been given an average recommendation of “Hold” by the five analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $32.00.

Several equities research analysts recently weighed in on OKUR shares. Wall Street Zen raised OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd.

Institutional Investors Weigh In On OnKure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Affinity Asset Advisors LLC grew its position in shares of OnKure Therapeutics by 173.4% in the first quarter. Affinity Asset Advisors LLC now owns 394,159 shares of the company’s stock valued at $1,695,000 after purchasing an additional 250,000 shares in the last quarter. Acorn Capital Advisors LLC boosted its stake in OnKure Therapeutics by 97.2% in the 2nd quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock worth $6,787,000 after purchasing an additional 1,400,000 shares during the period. Highbridge Capital Management LLC boosted its stake in OnKure Therapeutics by 51.2% in the 2nd quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock worth $1,586,000 after purchasing an additional 224,810 shares during the period. ADAR1 Capital Management LLC purchased a new position in OnKure Therapeutics during the 1st quarter valued at about $43,000. Finally, Shay Capital LLC increased its position in shares of OnKure Therapeutics by 17.4% during the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after buying an additional 135,888 shares during the period. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Trading Down 1.8%

NASDAQ:OKUR opened at $2.80 on Monday. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $9.40. The firm’s 50 day moving average is $3.03 and its 200 day moving average is $2.71. The stock has a market capitalization of $37.94 million, a PE ratio of -0.58 and a beta of 0.47.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.11. Research analysts predict that OnKure Therapeutics will post -4.05 earnings per share for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.